SLC7A11 and prostate carcinoma: In prostate cancer, SLC7A11 has been shown to sensitize tumors to ferroptosis inducers such as erastin and RSL3, which significantly inhibit tumor growth, especially when combined with second-generation antiandrogens like enzalutamide or abiraterone [24].